In recent years, metabolic syndrome has been a growing health concern across the world. The role of nutraceuticals and functional foods in this area has a significant place due to the adverse effects of contemporary modes of treatment. CurCousin ? is a nutritional ingredient containing bioactive Calebin A, (analog of Curcumin) with self-affirmed GRAS status. CurCousin ? has been a clinically studied dietary supplement ingredient with a positive impact on body weight, lipid levels and metabolic health. Bioenhancers play an important role in increasing the bioavailability of the active in turn enhancing efficacy as well as reducing the dosage required to achieve the therapeutic effect. This study investigated the possible pharmacokinetic interaction between CurCousin ? at two different doses (2.25 and 4.5 mg/kg) in the presence and absence of BioPerine ? (0.27 mg/kg), a natural bioenhancer in Sprague-Dawley rats. The results revealed that the addition of BioPerine ? into CurCousin ? (2.25 mg/kg) half the dose when administered enhances the bioavailability and was equipotent to CurCousin ? (4.5 mg/kg) double the dose without BioPerine ?. Thus, leading to future clinical studies to evaluate its improved pharmacological efficacy as well as reduced therapeutic dosage.
In recent years, there has been an increased concern about metabolic health due to faulty food habits, sedentary lifestyles, mental exhaustion, and stress. Metabolic syndrome refers to an aggregate of metabolic dysfunctions including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension, which is posing a significant health and social concern [
Calebin A shows higher chemical stability in acidic and basic media in contrast to the noted instability of curcumin at higher pH values while sharing several physiological properties with curcumin [
CurCousin® is a patented nutritional ingredient containing 99% pure Calebin A with a self-affirmed GRAS status. CurCousin® has shown promising activity in managing the risk factors of metabolic syndrome both in vitro and in vivo. Clinical findings showed that CurCousin® (Calebin A) may be an effective supplement
for managing abdominal obesity, dyslipidemia, and systemic inflammation in individuals with metabolic syndrome [
This study was undertaken to determine the effect of CurCousin® at two different doses (2.25 mg/kg and 4.5 mg/kg) in Sprague-Dawley rats and to evaluate whether the addition of natural bioenhancer, BioPerine® (0.27 mg/kg), a safe food component can increase the bioavailability at a lower dose making it almost equivalent to double dose. One such well-recognized natural bioenhancer in the market, backed by several clinical studies is BioPerine®. BioPerine® is prepared from the dried fruits of Piper nigrum (black pepper), standardized to 95% piperine with self-affirmed GRAS status. Multiple studies have been reported to confirm that BioPerine® significantly improves bioavailability when co-administered with various compounds through their increased absorption. Compounds such as curcumin, resveratrol, ginseng, β-carotene, coenzyme Q10, minerals (elemental iron, selenium), and vitamins (vitamin B6, vitamin C) were shown to enhance the bioavailability through increased absorption when administered with BioPerine® [
The test materials, CurCousin® (Calebin A) and BioPerine® (Piper nigrum extract), used for the study were supplied by Sami-Sabinsa Group Limited. CurCousin® containing the bioactive Calebin A (analog of Curcumin), occurs only in trace amounts in the turmeric rhizomes. It was chemically synthesized with >99% purity by HPLC. BioPerine® prepared from the dried fruits of Piper nigrum, through a solvent extraction process was standardized to contain a minimum of 95% piperine by HPLC. CurCousin® has been clinically studied as a dietary supplement ingredient with a positive impact on body weight, lipid levels and metabolic health. With the addition of BioPerine®, it significantly enhances bioavailability through their increased absorption.
All other chemicals/reagents and solvents used throughout the experiment were of analytical grade.
The experimental protocol was initiated after obtaining the permission from the Institutional Animal Ethics Committee (IAEC), Karnataka, India. Female young adult Sprague-Dawley rats, with body weights ranging between 180 and 200 g, aged between 8 and 10 weeks were used in this study. The animals were housed in the animal facility of Sri Adichunchanagiri College of Pharmacy, Karnataka. All experimental procedures were carried out as per the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines for laboratory animals under standard animal house conditions. Throughout the study, the animals were kept in polypropylene cages, under standard laboratory conditions. The temperature was kept at 22˚C ± 3˚C with a relative humidity of 30% - 70%, and a 12-hour light/ dark cycle with adequate fresh air supply (minimum of 12 - 16 air changes per hour). Daily temperature and relative humidity were recorded. Animals were kept in clean and sieved paddy husks. All animals were acclimatized to laboratory conditions for at least five days prior to the experiment. All animals had free access to food and water ad libitum.
The healthy young adult female animals were administered a single oral (gavage) dose of test material (CurCousin®) in the presence or absence of co-administration with BioPerine®. Before the test material administration, the animals were fasted overnight and allowed free access to water prior to the pharmacokinetic study. To perform pharmacokinetic studies, the experimental animals weighing 180-200 g were divided into two groups of different treatments and the groups were further subdivided into three subgroups of three animals each.
The animals were allotted by randomization and stratification to all the groups. Group I was administered as a standalone CurCousin® with a dose of 4.5 mg/kg while Group II was administrated with a single dose of 2.25 mg/kg CurCousin® along with 0.27 mg/kg BioPerine®, both orally. The grouping and respective doses are explained in
Blood samples were collected from individual animals by orbital venous plexus in Eppendorf tube containing dipotassium ethylenediaminetetraacetic acid (K2-EDTA) as anticoagulant, at predetermined time intervals (0 min, 15 min, 30 min, 1, 2, 4, 12 and 24 h) after test material administration. The plasma was separated by centrifuging the blood samples at 3000 rpm for 10 minutes and immediately frozen at −80˚C until analysis.
| Test group + dose (human equivalent dose) | Test group + dose (rat equivalent dose) | Sub-groups | No. of animals | Blood sampling Time points (8) | ||
|---|---|---|---|---|---|---|
| Group I CurCousin® (50 mg) | CurCousin® (4.5 mg/kg b.w) | Group 1 | 3 | 0 min | 1 h | 12 h |
| Group 2 | 3 | 15 min | 2 h | 24 h | ||
| Group 3 | 3 | 30 min | 4 h | - | ||
| Group II CurCousin® + BioPerine® (25 mg + 3 mg) | CurCousin®+BioPerine® (2.25 mg/kg + 0.27 mg/kg b.w) | Group 1 | 3 | 0 min | 1 h | 12 h |
| Group 2 | 3 | 15 min | 2 h | 24 h | ||
| Group 3 | 3 | 30 min | 4 h | - | ||
The test materials were administered as a single dose through oral route by gavage to each animal, using gavaging needle fitted onto a disposable syringe of appropriate size. The body weight of individual animals was recorded at the beginning before the administration of the test item. Prior to dosing and during the study period, the animals were observed for clinical signs and pre-terminal deaths periodically at 15th min, 30th min, 1st h, 2nd h, 4th h, 12th h and 24th h. Cage-side observations like changes in the skin and fur, eyes, mucous membranes, also respiratory, circulatory, and autonomic and central nervous systems, motor activity, and behavior patterns of animals were observed and recorded. Observations were also directed at the observation of tremors, convulsions, salivation, diarrhea, lethargy, sleep, and coma. The animals were subjected to detailed veterinary examination prior to test item administration. Changes in skin and fur, eyes, mucous membrane, occurrence of secretions and excretions, autonomic activities, response to handling, changes in gait, posture, clonic or tonic movements, stereotypic and bizarre behaviors of animals were recorded. At the end of the experimental period, all the animals were sacrificed by carbon dioxide asphyxiation method using chamber and subjected to necropsy. External and internal gross pathological observations were recorded.
The LC-MS/MS analysis was performed using the LC-MS/MS instrument, Water ZEVO TQS analyst 4.1 version. The LC-MS/MS system consisted of an HPLC system and a tandem mass spectrometer with (+) ESI. The analytical column Acquity UPLC BEH (C18, 2.1 × 100) was used for chromatographic separation. The mobile phase was a mixture of 0.1% Formic Acid: Acetonitrile (Gradient). The injection volume was 10 mL. MRM transition for Calebin A: 385.09 > 176.83 (q1 to q2).
The plasma samples for LC-MS/MS analysis were prepared by the protein precipitation method. At the time of analysis, plasma samples were removed from the deep freezer and thawed at room temperature. Sample preparation was carried out by adding plasma (50 µL) to 2 mL centrifuge tube and acetonitrile (150 µL) as precipitating agent. The samples were vortexed for 2 min and centrifuged at 4000 rpm for 7 min. After centrifugation, the supernatant layer was separated and was injected to the LC-MS/MS system for analysis.
A calibration curve is the relationship between instrument response and known concentrations of the analyte. A calibration curve should be generated for each analyte in the sample. A sufficient number of standards should be used to adequately define the relationship between concentration and response. A calibration curve should be prepared in the same biological matrix as the samples in the intended study by spiking the matrix with known concentrations of the analyte. The number of standards used in constructing a calibration curve will be a function of the anticipated range of analytical values and the nature of the analyte/response relationship. Concentrations of standards should be chosen based on the concentration range expected in a particular study. A calibration curve should consist of a blank sample (matrix sample processed without internal standard/molecule of interest for analysis), and six to eight non-zero samples covering the expected range, including the lowest limit of quantification (LLOQ).
The pharmacokinetic parameters such as peak plasma concentration (Cmax), time to peak concentration (Tmax), and area under the plasma concentration-time curve (AUC0-t), were calculated based on concentration over time by using pk1 and pk2 software. Area under the curve (AUC) is an important parameter in the field of pharmacokinetics and used commonly to assess the extent of exposure of a test material and its clearance rate from the body. The AUC (from zero to infinity) represents the total test material exposure with time in blood. In addition, AUC is useful for the therapeutic test material monitoring of test material with a narrow therapeutic index. The Cmax is the maximum (or peak) serum concentration that a test material achieves in a specified compartment or test area of the body after the test material has been administered and Tmax is the time required for a test material to reach Cmax. For oral administration, Cmax and Tmax are dependent on the extent, the rate of drug absorption and the disposition profile of the test material. The Cmax is often measured to show bioequivalence between a generic and innovator test material. According to the FDA, bioavailability and bioequivalence rely on pharmacokinetic measurements such as AUC and Cmax which demonstrates systemic exposure of the test material. The elimination rate constant (Kel) describes the rate at which test material is removed from the body. We can calculate the half-life of test material from Kel, if the clearance of test material is very high, Kel is high resulting short half-life and vice versa.
The body weight of individual animals was recorded at the beginning before administration of the test material. During the study period, no treatment related changes were observed in any of the groups, indicating the test material did not have any adverse effect on body weight. The summary of body weight measurements is depicted in
All the animals were observed for any clinical signs and pre-terminal deaths periodically at 15th min, 30th min, 1st h, 2nd h, 4th h, 12th h and 24th h following dosing. During the study period no-treatment related changes in clinical signs of
| Test group + dose | Sub-groups | Weekly body weights (gm) | |
|---|---|---|---|
| Initial | 24 hours after test item administration | ||
| Group I CurCousin® (4.5 mg/kg b.w) | Group 1 | 200 | 197 |
| 198 | 195 | ||
| 192 | 189 | ||
| Group 2 | 194 | 191 | |
| 185 | 182 | ||
| 188 | 185 | ||
| Group 3 | 184 | 181 | |
| 186 | 183 | ||
| 190 | 187 | ||
| Group II CurCousin® + BioPerine® (2.25 mg/kg + 0.27 mg/kg b.w) | Group 1 | 190 | 187 |
| 185 | 183 | ||
| 188 | 185 | ||
| Group 2 | 184 | 182 | |
| 186 | 183 | ||
| 190 | 188 | ||
| Group 3 | 189 | 186 | |
| 192 | 188 | ||
| 195 | 192 | ||
| Test group | Group I CurCousin® (4.5 mg/kg) | Group II CurCousin® + BioPerine® (2.25 mg/kg + 0.27 mg/kg) |
|---|---|---|
| Skin and Fur | 0 | 0 |
| Eyes | 0 | 0 |
| Mucous membrane | 0 | 0 |
| Occurrence of secretions and excretions | ||
| - Salivation | 0 | 0 |
| - Urine staining | 0 | 0 |
| - Fecal staining or diarrhea | 0 | 0 |
| - Nasal discharge | 0 | 0 |
| Autonomic activity | ||
| - Lacrimation | 0 | 0 |
| - Piloerection | 0 | 0 |
| - Pupil size or pupillary | 0 | 0 |
| - Unusual respiratory | 0 | 0 |
| Response to handling | 0 | 0 |
| Changes in gait | 0 | 0 |
| Posture | 0 | 0 |
| Clonic or tonic movements | 0 | 0 |
| Stereotypic behavior | ||
| - Repetitive circling | 0 | 0 |
| - Excessive grooming | 0 | 0 |
| Bizarre behavior | ||
| - Self-mutilation | 0 | 0 |
| - Walking backwards | 0 | 0 |
n = 3; “0”: Absence of clinical sign.
toxicity, pre-terminal mortality and abnormal behaviors were observed in any of the groups.
During the study period, the animals were subjected to detailed clinical veterinary examination (
The LC-MS/MS method was effectively used to analyse the chemical constituent after administration of CurCousin® in female Sprague-Dawley rats. LC-MS/MS chromatogram of the chemical constituent, Calebin A is shown in Figures 2(a)-(c). The concentration range for the calibration curve of Calebin A was 1 ng/mL to 50 ng/mL and r2 was observed 0.99. The lower limit of quantification (LLOQ) was ~0.8 ng/mL (
After oral administration of BioPerine®, the plasma concentration versus the time profile of CurCousin® are shown in
The data demonstrated that AUC0-24h of CurCousin® at a lower dose of 2.25 mg/kg along with BioPerine® (0.27 mg/kg) was almost similar to double the dose of CurCousin® (4.5 mg/kg) without BioPerine®. Thus, the bioavailability of CurCousin® (2.25 mg/kg) with addition of BioPerine® (0.27 mg/kg) enhanced to 97.44% compared to stand-alone CurCousin® (4.5 mg/kg) which was almost similar. Overall, the data demonstrated that addition of BioPerine® (0.27 mg/kg) has enhanced the bioavailability of CurCousin® (2.25 mg/kg) equivalent to that of CurCousin® (4.5 mg/kg).
| Pharmacokinetic parameters | Group I CurCousin® (4.5 mg/kg) | Group II CurCousin® + BioPerine® (2.25 + 0.27 mg/kg) | Bioavailability of Calebin A in CurCousin® (4.5 mg/kg) compared to CurCousin® + BioPerine® (2.25 + 0.27 mg/kg) |
|---|---|---|---|
| Cmax (ng/mL) | 1.3496 | 1.2293 | 97.44% |
| Tmax (h) | 2 | 4 | |
| Kel (h) | 0.0286 | 0.0350 | |
| t1/2 (h) | 24.2434 | 19.7917 | |
| AUC0-24 (ng∙h/mL) | 19.0769 | 18.5891 | |
| AUC0-∞ (ng∙h/mL) | 53.3480 | 45.1119 |
Coax: Maximum observed concentration; Tmax: Maximum observed time; Kel: Elimination rate constant; t1/2: Half-life; AUC: Area under the curve; AUC0-24: Area under the curve 0 - 24 h; AUC0-∞: Area under the curve zero to infinity. Compared statistically: CurCousin® (Group 1) vs. CurCousin® + BioPerine® (Group 2) p values: Cmax 0.213; AUC0-24 0.465; AUC0-∞ 0.923.
In the modern era, lifestyle changes have brought a major setback in metabolic health. Metabolic syndrome has become a serious health concern across the world. The role of nutraceuticals emerges to be highly crucial due to the potential side-effects of contemporary mode of treatment. Bioenhancers are compounds that help to enhance the bioavailability of the active substance through increased absorption by enhancing the efficacy as well as reducing the dosage required to achieve the therapeutic effect. In this study, BioPerine®, a natural bioenhancer has been used, which has been proven to significantly improve the bioavailability when co-administered with various compounds such as curcumin, resveratrol, ginseng, β-carotene [
The study concluded that the AUC0-24h of CurCousin® (2.25 mg/kg) administered with BioPerine® (0.27 mg/kg) had 97.44% increase which is almost equal to CurCousin® (4.5 mg/kg), inferring that CurCousin® half the dose when administered with BioPerine® was equipotent to CurCousin® double the dose without BioPerine®. Overall, this study demonstrated that, addition of BioPerine® enhanced the bioavailability of CurCousin®, thereby paving way for future clinical studies on CurCousin® with BioPerine® to investigate its improved pharmacological efficacy and reduced dosage of active making more consumer friendly.
In the present study, the results of the pharmacokinetic investigation revealed that co-administration of BioPerine® significantly improved the pharmacokinetic parameters of CurCousin®. The study demonstrated that the addition of BioPerine® can enhance the bioavailability and bioefficacy of CurCousin® by reducing the effective dose of CurCousin® from 4.5 mg/kg bw to half the dose of 2.25 mg/kg bw.
The authors have no conflict of interest to disclose.
Majeed, M., Nagabhushanam, K., Bani, S., Pandey, A. and Thazhathidath, S. (2024) Enhancement in Bioavailability of CurCousin®, a Minor Metabolite from Curcuma longa by Addition of BioPerine®—A Pharmacokinetic Study. Journal of Biosciences and Medicines, 12, 282-293. https://doi.org/10.4236/jbm.2024.122022